Announcement • Jun 30
Hanshang Group Co., Ltd. to Report First Half, 2026 Results on Aug 25, 2026 Hanshang Group Co., Ltd. announced that they will report first half, 2026 results on Aug 25, 2026 Reported Earnings • Apr 29
Full year 2025 earnings released: CN¥0.59 loss per share (vs CN¥0.049 loss in FY 2024) Full year 2025 results: CN¥0.59 loss per share (further deteriorated from CN¥0.049 loss in FY 2024). Revenue: CN¥1.03b (down 12% from FY 2024). Net loss: CN¥174.8m (loss widened CN¥160.2m from FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 106 percentage points per year, which is a significant difference in performance. Announcement • Apr 29
Hanshang Group Co., Ltd., Annual General Meeting, May 19, 2026 Hanshang Group Co., Ltd., Annual General Meeting, May 19, 2026, at 14:30 China Standard Time. Location: 8F, No. 134, Hanyang Avenue, Hanyang District, Wuhan, Hubei China Announcement • Mar 30
Hanshang Group Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 Hanshang Group Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 New Risk • Mar 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 27% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.5% average weekly change). Announcement • Dec 26
Hanshang Group Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026 Hanshang Group Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026 Reported Earnings • Oct 31
Third quarter 2025 earnings released: EPS: CN¥0.026 (vs CN¥0.02 loss in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.026 (up from CN¥0.02 loss in 3Q 2024). Revenue: CN¥250.9m (down 9.7% from 3Q 2024). Net income: CN¥7.70m (up CN¥13.7m from 3Q 2024). Profit margin: 3.1% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 91 percentage points per year, which is a significant difference in performance. Announcement • Sep 30
Hanshang Group Co., Ltd. to Report Q3, 2025 Results on Oct 31, 2025 Hanshang Group Co., Ltd. announced that they will report Q3, 2025 results on Oct 31, 2025 Announcement • Jun 30
Hanshang Group Co., Ltd. to Report First Half, 2025 Results on Aug 28, 2025 Hanshang Group Co., Ltd. announced that they will report first half, 2025 results on Aug 28, 2025 New Risk • May 10
New major risk - Revenue and earnings growth Earnings have declined by 5.1% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.1% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.9% average weekly change). New Risk • May 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Apr 30
Hanshang Group Co., Ltd., Annual General Meeting, May 20, 2025 Hanshang Group Co., Ltd., Annual General Meeting, May 20, 2025, at 14:30 China Standard Time. Location: 8F, No. 134, Hanyang Avenue, Hanyang District, Wuhan, Hubei China Announcement • Mar 28
Hanshang Group Co., Ltd. to Report Q1, 2025 Results on Apr 30, 2025 Hanshang Group Co., Ltd. announced that they will report Q1, 2025 results on Apr 30, 2025 Announcement • Dec 27
Hanshang Group Co., Ltd. to Report Fiscal Year 2024 Results on Apr 10, 2025 Hanshang Group Co., Ltd. announced that they will report fiscal year 2024 results on Apr 10, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: CN¥0.02 loss per share (vs CN¥0.07 profit in 3Q 2023) Third quarter 2024 results: CN¥0.02 loss per share (down from CN¥0.07 profit in 3Q 2023). Revenue: CN¥277.8m (down 12% from 3Q 2023). Net loss: CN¥6.02m (down 129% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 24% per year, which means it has not declined as severely as earnings. Announcement • Sep 30
Hanshang Group Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Hanshang Group Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Reported Earnings • Aug 16
Second quarter 2024 earnings released: CN¥0.014 loss per share (vs CN¥0.081 profit in 2Q 2023) Second quarter 2024 results: CN¥0.014 loss per share (down from CN¥0.081 profit in 2Q 2023). Revenue: CN¥289.4m (down 15% from 2Q 2023). Net loss: CN¥4.16m (down 117% from profit in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Announcement • Jun 28
Hanshang Group Co., Ltd. to Report First Half, 2024 Results on Aug 16, 2024 Hanshang Group Co., Ltd. announced that they will report first half, 2024 results on Aug 16, 2024 Valuation Update With 7 Day Price Move • Jun 25
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥8.16, the stock trades at a trailing P/E ratio of 47.5x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 46% over the past three years. Valuation Update With 7 Day Price Move • Jun 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥8.79, the stock trades at a trailing P/E ratio of 51.2x. Average trailing P/E is 29x in the Pharmaceuticals industry in China. Total loss to shareholders of 42% over the past three years. New Risk • May 13
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 57% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (3.6% net profit margin). Valuation Update With 7 Day Price Move • May 09
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to CN¥9.02, the stock trades at a trailing P/E ratio of 52.5x. Average trailing P/E is 32x in the Pharmaceuticals industry in China. Total loss to shareholders of 33% over the past three years. Reported Earnings • Apr 27
First quarter 2024 earnings released: EPS: CN¥0.043 (vs CN¥0.082 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.043 (down from CN¥0.082 in 1Q 2023). Revenue: CN¥336.6m (down 6.9% from 1Q 2023). Net income: CN¥12.7m (down 48% from 1Q 2023). Profit margin: 3.8% (down from 6.7% in 1Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has only fallen by 26% per year, which means it has not declined as severely as earnings. Announcement • Apr 27
Hanshang Group Co., Ltd., Annual General Meeting, May 16, 2024 Hanshang Group Co., Ltd., Annual General Meeting, May 16, 2024, at 14:30 China Standard Time. Location: 8F, No. 134, Hanyang Avenue, Hanyang District, Wuhan, Hubei China Valuation Update With 7 Day Price Move • Apr 16
Investor sentiment deteriorates as stock falls 21% After last week's 21% share price decline to CN¥6.30, the stock trades at a trailing P/E ratio of 19.8x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 58% over the past three years. Announcement • Mar 29
Hanshang Group Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Hanshang Group Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Valuation Update With 7 Day Price Move • Mar 06
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to CN¥8.30, the stock trades at a trailing P/E ratio of 26.1x. Average trailing P/E is 27x in the Pharmaceuticals industry in China. Total loss to shareholders of 46% over the past three years. Buy Or Sell Opportunity • Mar 05
Now 27% overvalued Over the last 90 days, the stock has fallen 16% to CN¥8.56. The fair value is estimated to be CN¥6.76, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Meanwhile, the company has become profitable. New Risk • Feb 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (229% cash payout ratio). Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to CN¥6.61, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 25x in the Pharmaceuticals industry in China. Total loss to shareholders of 55% over the past three years. Valuation Update With 7 Day Price Move • Feb 05
Investor sentiment deteriorates as stock falls 27% After last week's 27% share price decline to CN¥6.09, the stock trades at a trailing P/E ratio of 19.2x. Average trailing P/E is 23x in the Pharmaceuticals industry in China. Total loss to shareholders of 56% over the past three years. Valuation Update With 7 Day Price Move • Jan 22
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to CN¥8.24, the stock trades at a trailing P/E ratio of 26x. Average trailing P/E is 28x in the Pharmaceuticals industry in China. Total loss to shareholders of 42% over the past three years. Announcement • Dec 29
Hanshang Group Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024 Hanshang Group Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024 Reported Earnings • Oct 29
Third quarter 2023 earnings released: EPS: CN¥0.07 (vs CN¥0.078 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.07 (down from CN¥0.078 in 3Q 2022). Revenue: CN¥315.0m (down 2.5% from 3Q 2022). Net income: CN¥20.7m (down 10% from 3Q 2022). Profit margin: 6.6% (down from 7.1% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Hanshang Group Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023 Hanshang Group Co., Ltd. announced that they will report Q3, 2023 results at 3:00 PM, China Standard Time on Oct 28, 2023 Reported Earnings • Aug 26
Second quarter 2023 earnings released: EPS: CN¥0.081 (vs CN¥0.066 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.081 (up from CN¥0.066 in 2Q 2022). Revenue: CN¥339.8m (down 1.1% from 2Q 2022). Net income: CN¥24.0m (up 24% from 2Q 2022). Profit margin: 7.0% (up from 5.6% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 9% per year, which means it is significantly lagging earnings. Announcement • Jun 28
Hanshang Group Co., Ltd. to Report First Half, 2023 Results on Aug 26, 2023 Hanshang Group Co., Ltd. announced that they will report first half, 2023 results on Aug 26, 2023 Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.082 (vs CN¥0.079 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.082 (up from CN¥0.079 in 1Q 2022). Revenue: CN¥361.4m (up 1.2% from 1Q 2022). Net income: CN¥24.3m (up 4.3% from 1Q 2022). Profit margin: 6.7% (up from 6.5% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 43% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Announcement • Jan 13
Hanshang Group Co., Ltd. (SHSE:600774) agreed to acquire 81.34% stake in Wuhan Tongji Technology Group Co., Ltd. Hanshang Group Co., Ltd. (SHSE:600774) agreed to acquire 81.34% stake in Wuhan Tongji Technology Group Co., Ltd. on November 4, 2022. Hanshang Group won the bid for stake in Wuhan Tongji Technology Group . As the winner of the bid, Hanshang Group Co., Ltd paid a deposit of CNY 20 million. Buying Opportunity • Dec 19
Now 26% undervalued Over the last 90 days, the stock is up 8.2%. The fair value is estimated to be CN¥16.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 21% over the last 3 years. Earnings per share has grown by 53%. Valuation Update With 7 Day Price Move • Dec 12
Investor sentiment improved over the past week After last week's 19% share price gain to CN¥14.86, the stock trades at a trailing P/E ratio of 42.7x. Average trailing P/E is 34x in the Multiline Retail industry in China. Total returns to shareholders of 39% over the past three years. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Supervisor Yu Xia was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 30
Third quarter 2022 earnings released: EPS: CN¥0.078 (vs CN¥0.071 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.078 (up from CN¥0.071 in 3Q 2021). Revenue: CN¥322.9m (down 13% from 3Q 2021). Net income: CN¥23.0m (up 43% from 3Q 2021). Profit margin: 7.1% (up from 4.3% in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Reported Earnings • Sep 02
Second quarter 2022 earnings released: EPS: CN¥0.066 (vs CN¥0.087 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.066 (down from CN¥0.087 in 2Q 2021). Revenue: CN¥343.6m (down 7.1% from 2Q 2021). Net income: CN¥19.4m (down 1.5% from 2Q 2021). Profit margin: 5.6% (up from 5.3% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 58% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Announcement • May 26
Hanshang Group Co., Ltd. (SHSE:600774) announces an Equity Buyback for CNY 150 million worth of its shares. Hanshang Group Co., Ltd. (SHSE:600774) announces a share repurchase program. Under the program, the company will repurchase up to CNY 150 million worth of shares. The program is valid for 12 months. Upcoming Dividend • May 03
Upcoming dividend of CN¥0.10 per share Eligible shareholders must have bought the stock before 10 May 2022. Payment date: 10 May 2022. Payout ratio is a comfortable 28% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Chinese dividend payers (2.3%). Lower than average of industry peers (3.5%). Reported Earnings • May 02
First quarter 2022 earnings released: EPS: CN¥0.079 (vs CN¥0.098 in 1Q 2021) First quarter 2022 results: EPS: CN¥0.079. Revenue: CN¥357.3m (down 3.0% from 1Q 2021). Net income: CN¥23.3m (up 4.1% from 1Q 2021). Profit margin: 6.5% (up from 6.1% in 1Q 2021). Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 12 experienced directors. No highly experienced directors. 3 independent directors (7 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Apr 03
Full year 2021 earnings released: EPS: CN¥0.35 (vs CN¥0.20 in FY 2020) Full year 2021 results: EPS: CN¥0.35 (up from CN¥0.20 in FY 2020). Revenue: CN¥1.48b (up 198% from FY 2020). Net income: CN¥85.7m (up 88% from FY 2020). Profit margin: 5.8% (down from 9.2% in FY 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 66% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Mar 10
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥13.49, the stock trades at a trailing P/E ratio of 22.9x. Average trailing P/E is 23x in the Multiline Retail industry in China. Total loss to shareholders of 5.2% over the past three years. Valuation Update With 7 Day Price Move • Jan 27
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥14.78, the stock trades at a trailing P/E ratio of 25.1x. Average trailing P/E is 25x in the Multiline Retail industry in China. Total returns to shareholders of 38% over the past three years. Reported Earnings • Oct 31
Third quarter 2021 earnings released: EPS CN¥0.071 (vs CN¥0.11 loss in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: CN¥371.4m (up 443% from 3Q 2020). Net income: CN¥16.1m (up CN¥40.9m from 3Q 2020). Profit margin: 4.3% (up from net loss in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 67% per year but the company’s share price has only increased by 13% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 31
Second quarter 2021 earnings released: EPS CN¥0.087 (vs CN¥0.079 loss in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥369.9m (up CN¥317.4m from 2Q 2020). Net income: CN¥19.7m (up CN¥37.6m from 2Q 2020). Profit margin: 5.3% (up from net loss in 2Q 2020). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Announcement • Aug 18
Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) completed the acquisition of 31% stake in Tongji Medical College Huazhong University of Science and Technology Reproductive Medicine Center from Wuhan Century Jiasheng Institute of Reproductive Medicine (Limited Partnership), Su Nan and Lia Hua. Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) entered into an agreement to acquire 31% stake in Tongji Medical College Huazhong University of Science and Technology Reproductive Medicine Center from Wuhan Century Jiasheng Institute of Reproductive Medicine (Limited Partnership), Su Nan and Lia Hua for CNY 71.3 million on July 10, 2020. Under the terms, Wuhan Century will give up 16% stake, Liu Hua will give up 5% stake and Su Nan will give up 10% stake as a part of the transaction. Tongji Medical College Huazhong University of Science and Technology Reproductive Medicine Center reported total assets of CNY 55.2 million, net assets of CNY 14.7 million, revenues of CNY 64.4 million. The transaction does not require approval from shareholders of Wuhan Hanshang. The transaction has been approved by the Board of Wuhan Hanshang.
Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) completed the acquisition of 31% stake in Tongji Medical College Huazhong University of Science and Technology Reproductive Medicine Center from Wuhan Century Jiasheng Institute of Reproductive Medicine (Limited Partnership), Su Nan and Lia Hua on August 17, 2021. After the transaction Wuhan Hanshang Group has 31%, Wuhan Century Jiasheng Institute has 14%, Wuhan Tongji Technology has 20%, Yin Ming has 25% and Liu Hua has 10% in Tongji Medical College Huazhong. Valuation Update With 7 Day Price Move • May 31
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥15.06, the stock trades at a trailing P/E ratio of 35.9x. Average trailing P/E is 24x in the Multiline Retail industry in China. Total returns to shareholders of 17% over the past three years. Valuation Update With 7 Day Price Move • May 10
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥13.86, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 25x in the Multiline Retail industry in China. Total returns to shareholders of 10% over the past three years. Reported Earnings • May 04
First quarter 2021 earnings released: EPS CN¥0.098 (vs CN¥0.12 loss in 1Q 2020) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2021 results: Revenue: CN¥368.4m (up CN¥331.3m from 1Q 2020). Net income: CN¥22.3m (up CN¥49.7m from 1Q 2020). Profit margin: 6.1% (up from net loss in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 9% per year. Reported Earnings • Apr 01
Full year 2020 earnings released: EPS CN¥0.20 (vs CN¥0.13 in FY 2019) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2020 results: Revenue: CN¥495.2m (down 57% from FY 2019). Net income: CN¥45.5m (up 52% from FY 2019). Profit margin: 9.2% (up from 2.6% in FY 2019). Over the last 3 years on average, earnings per share has fallen by 39% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Announcement • Mar 09
Wuhan Hanshang Group Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 31, 2021 Wuhan Hanshang Group Co.,Ltd. announced that they will report fiscal year 2020 results on Mar 31, 2021 Is New 90 Day High Low • Feb 26
New 90-day high: CN¥15.61 The company is up 14% from its price of CN¥13.65 on 27 November 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Multiline Retail industry, which is down 13% over the same period. Is New 90 Day High Low • Jan 19
New 90-day high: CN¥13.82 The company is up 21% from its price of CN¥11.43 on 21 October 2020. The Chinese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Multiline Retail industry, which is down 19% over the same period. Reported Earnings • Oct 29
Third quarter earnings released Over the last 12 months the company has reported total losses of CN¥67.7m, with earnings decreasing by CN¥103.6m from the prior year. Total revenue was CN¥516.1m over the last 12 months, down 53% from the prior year. Is New 90 Day High Low • Oct 21
New 90-day low: CN¥11.43 The company is down 21% from its price of CN¥14.52 on 23 July 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Multiline Retail industry, which is down 15% over the same period. Is New 90 Day High Low • Oct 01
New 90-day low: CN¥11.56 The company is down 5.0% from its price of CN¥12.14 on 03 July 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Multiline Retail industry, which is down 3.0% over the same period. Announcement • Sep 24
Hanshang Great Health Industry Co., Ltd. and Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) entered into an agreement to acquire Chengdu Dikang Pharmaceutical Co., Ltd. from Sichuan Blu-ray Development Co., Ltd. and Chengdu Landi Shared Enterprise Management Partnership (Limited Partnership) for CNY 900 million. Hanshang Great Health Industry Co., Ltd. and Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) entered into an agreement to acquire Chengdu Dikang Pharmaceutical Co., Ltd. from Sichuan Blu-ray Development Co., Ltd. and Chengdu Landi Shared Enterprise Management Partnership (Limited Partnership) for CNY 900 million on July 28, 2020. Hanshang Great Health Industry Co., Ltd. and Wuhan Hanshang Group Co.,Ltd. will acquire 120 million shares. The transaction price of this share transfer is paid in two installments. Payment of the first transfer price within 5 working days after the delivery of the underlying shares, Wuhan Hanshang Group Co.,Ltd. and Hanshang Great Health Industry Co., Ltd. will pay the counterparty 51% of the share transfer price and payment of the second phase of the transfer price before May 31, 2021, Wuhan Hanshang Group Co.,Ltd. and Hanshang Great Health Industry Co., Ltd. will pay the remaining 49% of the equity transfer price. The transaction will be financed from its own funds, self-raised funds and a non-public issuance of A shares. For the year ending December 31, 2019, Chengdu Dikang Pharmaceutical Co., Ltd. reported total assets of CNY 1.08 billion, shareholder's equity of CNY 484.42 million, revenues of CNY 1.07 billion and net profit of CNY 135.98 million. The transaction is subject to the approval of board of Wuhan Hanshang Group Co.,Ltd., shareholders of Wuhan Hanshang Group Co.,Ltd. and the State Administration for Market Regulation. Wang Changqing of China Securities Co., Ltd. acted as financial advisor while Tan Sijun and Cheng Xuan of Jiayuan Law acted as legal advisors and Huang Xiaohua and Chen Gang of Union Power Certified Public Accountants Co., Ltd acted as accountants to Wuhan Hanshang Group Co.,Ltd. Announcement • Sep 08
Wuhan Hanyang Holding Group Co., Ltd cancelled the acquisition of 35.01% stake in Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) from Wuhan Hanyang District State-owned Assets Supervision & Administration Office. Wuhan Hanyang Holding Group Co., Ltd signed free transfer agreement to acquire 35.01% stake in Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) from Wuhan Hanyang District State-owned Assets Supervision & Administration Office for CNY 0 on July 1, 2019. On July 1, 2019, the State-owned Assets Supervision and Administration Commission of Wuhan agreed to the transaction. The transaction is exempted from an approval by China Securities Regulatory Commission Administrative.
Wuhan Hanyang Holding Group Co., Ltd cancelled the acquisition of 35.01% stake in Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) from Wuhan Hanyang District State-owned Assets Supervision & Administration Office on July 1, 2020. Announcement • Jul 31
Wuhan Hanshang Group Co.,Ltd. announced that it expects to receive CNY 1.285 billion in funding Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) announced a private placement of not more than 68,084,400 shares for gross proceeds of not more than CNY 1,285,000,000 on July 28, 2020. The transaction will include participation from not more than 35 specific investors. The transaction has been approved in the 14th meeting of the company's tenth directorate, and is subject to approval in the another board of directors meeting, general meeting of shareholders, and from China Securities Regulatory Commission. The validity period of the transaction is 12 months from the date of approval in the company's shareholders' meeting. Announcement • Jul 17
Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) entered into an agreement to acquire 31% stake in Tongji Medical College Huazhong University of Science and Technology Reproductive Medicine Center from Wuhan Century Jiasheng Institute of Reproductive Medicine (Limited Partnership), Su Nan and Lia Hua for CNY 71.3 million. Wuhan Hanshang Group Co.,Ltd. (SHSE:600774) entered into an agreement to acquire 31% stake in Tongji Medical College Huazhong University of Science and Technology Reproductive Medicine Center from Wuhan Century Jiasheng Institute of Reproductive Medicine (Limited Partnership), Su Nan and Lia Hua for CNY 71.3 million on July 10, 2020. Under the terms, Wuhan Century will give up 16% stake, Liu Hua will give up 5% stake and Su Nan will give up 10% stake as a part of the transaction. Tongji Medical College Huazhong University of Science and Technology Reproductive Medicine Center reported total assets of CNY 55.2 million, net assets of CNY 14.7 million, revenues of CNY 64.4 million. The transaction does not require approval from shareholders of Wuhan Hanshang. The transaction has been approved by the Board of Wuhan Hanshang. Announcement • Jul 10
Wuhan Hanshang Group Co.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020 Wuhan Hanshang Group Co.,Ltd. announced that they will report first half, 2020 results on Aug 28, 2020 
